@FORTRESSMEETING

FORTRESS (Forum for Translational Research in Sarcomas) is a platform for scientists sharing an interest in laboratory work related to mesenchymal malignancies

Joined January 2019
  • Tweets325
  • Following152
  • Followers485
40Media
My lab is hiring talented and motivated individuals at all levels of training. Our mission is to understand how epigenetic dysregulation drives sarcoma development and plasticity and to translate these insights into new therapies. Please apply at the following links.
4
34
93
7,099
Nuclear grading of myxoid liposarcoma demonstrates superior prognostic performance over conventional grading, which is traditionally based on the proportion of the round cell component. Read Marcelis L … Folpe AL doi.org/10.1007/s00428-026-0…
4
7
281
In 1986 José Maria Fernández Sousa-Faro founded PharmaMar with the objetive of developing anticancer drugs from marine resources. Trabectedin turned out to be a practice-changing drug for patients with lipo-, leiomyo- and translocation-related sarcomas. Congratulations PharmaMar!
2
4
1
14
1,611
Two novel synthetic ecteinascidins, ecubectedin and PM54, show impressive anti-tumor effects in leiomyo-, dediff. lipo-, synovial and CIC-rearranged sarcoma. Read doi.org/10.1158/2767-9764.CR…

Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma...

AbstractTrabectedin, prototype of the ecteinascidin class of drugs, is a known second- or later-line therapeutic option for advanced soft tissue sarcoma (STS). We evaluated the antitumor activity of...

aacrjournals.org
1
4
1
13
1,523
Development of CAR T therapy and first-in-human individual participant trial for patients with alveolar soft part sarcoma and other MiT/TFE-driven diseases. Spectacular academic initiative - congratulation to F. Zemp and D. Mahoney and their teams. DOI: 10.1038/s43018-026-01194-3
1
2
11
739
These results are nicely reflected by differences in the EMA vs. FDA label for avapritinib: EMA recommends the use in tumors carrying the imatinib-resistant D842V mutation, while FDA approved the drug for PDGFRa mutations in exon 18, including D842V. Which label do you prefer?
1
4
231
GIST with non-D842V PDGFRa mutations have a predicted 86.4 % chance to respond to good old imatinib. Not all exon 18 mutations are the same, not every patient requires toxic avapritinib. Read the comprehensive analysis by H.M. Khosroyani and M.C. Heinrich doi.org/10.1158/2767-9764.CR…

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to...

AbstractThe most common platelet-derived growth factor receptor α (PDGFRA) alteration in gastrointestinal stromal tumors (GIST) is the exon 18 activation loop mutation D842V, which is resistant to...

aacrjournals.org
1
7
13
1,173
Brightline-1 assessed the MDM2 antagonist brigimadlin vs doxorubicin in dedifferentiated liposarcoma in 1st line. mPFS 8.4 vs 7.2 mo, ORR 22.3 vs 8.6% (brigi vs doxo). PFS (doxo) was longer than anticipated, the primary endpoint was not met. doi: 10.1158/1078-0432.CCR-26-0509
3
10
619
Lore De Cock, PhD, has been awarded a VHIO International Postdoctoral Programme for Translational Research fellowship, will join César Serrano’s lab in October 2026. Congratulations! FORTRESS is connecting people and the promotor/co-promotor of your thesis are proud of you…
1
1
1
12
932
Basket trial of the EZH2 inhibitor tazemetostat demonstrated preliminary antitumor activity with responses in rhabdoid tumors, INI1-negative tumors and poorly differentiated chordomas. No responses seen in synovial sarcoma and renal medullary carcinoma. nature.com/articles/s41467-0…

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket...

Nature Communications - Tumours with alterations in SWI/SNF complex have elevated EZH2 activity, which is associated with poor prognosis and tumour progression. Here, the authors report a phase 2...

nature.com
1
7
1
18
2,276
It makes absolutely no sense to draw conclusions on the perceived efficacy of novel agents in sarcoma based on expansion cohorts in Phase I/II trials with only 25 patients included and not selected for subtype and/or molecular alteration. doi.org/10.1158/2767-9764.CR…

Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with...

AbstractPurpose:. AXL, a receptor tyrosine kinase related to oncogenic processes, is aberrantly expressed in various cancers and associated with treatment resistance. Enapotamab vedotin (EnaV), a...

aacrjournals.org
1
1
1
7
638
Urokinase plasminogen activator receptor-associated protein (uPARAP) is highly expressed in a variety of sarcoma subtypes and a promising target for antibody/drug conjugates. See authors.elsevier.com/sd/arti… and clinicaltrials.gov/study/NCT…
1
4
12
618
Successful and smooth FORTRESS 2026 in the Grand Beguinage at KU Leuven, Leuven (B). Mission accomplished!
5
14
624
Leuven hosted, we debated…The rest is confidential! Fortress 2026 – Mystery Edition ⁦@FORTRESSMEETING⁩ ⁦@schoffski⁩ ⁦@AgaWozniak1⁩
1
7
14
574
The 2026 edition of FORTRESS took off in the 800 year old „Infirmerie“ at KU Leuven‘s Grand Beguinage
3
15
567
Forum for Translational Research in Sarcomas (FORTRESS) returning to its birthplace Leuven (BE) this week! We are looking forward to welcoming 140 invited guests in our spectacular medieval environment, the Infirmerie, a care facility dating back almost 800 years
3
15
343
Suggestion from a former award winner: If you are affiliated to a university in EU or Switzerland & you work on tumours of the locomotor apparatus, apply for the Oswald Vander Veken Prize (25.000 Euro for personal use! Details: [email protected]. Deadline 02-03-2026! Goodluck 🩺
1
2
4
542
FORTRESS and FORTIFY scientific program for the 2026 workshop in Leuven (BE) shared with our registered attendees today. kuleuven.be/fortress. We are fully booked!

FORTRESS - Forum for Translational Research in Sarcomas

FORTRESS is a scientific initiative by the University Hospitals (UZ Leuven) of KU Leuven (Belgium) and the West German Cancer Center, University of Duisburg/Essen (Germany), an annual academic...

kuleuven.be
2
8
568
Death receptor 5 agonist ozekibart (INBRX-109) doubles PFS in pts with advanced or metastatic, IDH-mutated or -wildtype chondrosarcoma when compared to placebo, and delays deterioration in pain and other PROs. Read INHIBRx press release and Subbiah et al. Clin Cancer Res 2023
1
7
1
26
1,366
I wish all spider plots from sarcoma trials would look like the one from the recent update of the DeFi trial leading to regulatory approval of nirogacestat in US and Europe for our patients with desmoid fibromatosis. doi.org/10.1200/JCO-25-00582
7
22
957
Load more